Lantheus, RefleXion to collaborate on prostate cancer treatment

By staff writers

September 13, 2021 -- Lantheus Medical Imaging parent Lantheus Holdings and radiation therapy equipment developer RefleXion Medical have signed a development and marketing partnership to evaluate the use of Lantheus' prostate-specific membrane antigen (PSMA)-targeted PET agent piflufolastat F-18 with RefleXion's X1 biology-guided radiotherapy system.

RefleXion X1 combines PET technology with radiation therapy delivery, allowing for real-time treatment guidance using tumor biology, Lantheus said.

The agreement will be managed by a joint steering committee and will be focused on securing U.S. regulatory approval to treat patients with biology-guided radiotherapy using piflufolastat F-18.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking